الإحصائيات الأساسية
| LEI | 529900SSN4DODDQSN594 |
| CIK | 1177648 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Enanta Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 20, 2025 |
Exhibit 99.1 Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union WATERTOWN, Mass.—August 20, 2025- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unifi |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 11, 2025 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 • On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September • On Track to Select a STAT6 Development Candidate in 2H 2025 • Conducting IND Enabling Studies of EPS-1421, an Oral KIT Inhibitor |
|
| May 14, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 14, 2025 S-8 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 14, 2025 REGISTRATION NO. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 14, 2025 |
EX-FILING FEES EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Enanta Pharmaceuticals, Inc. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 12, 2025 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 • Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025 • STAT6 Program Progressing with Plans to Select a Development Candidate in 2H 2025 • IND Enabling Studi |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 17, 2025 |
2019 Equity Incentive Plan (as amended March 2025) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 13, 2025) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 12, 2025 |
2019 Equity Incentive Plan (as amended December 2024) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through December 20, 2024) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expect |
|
| February 12, 2025 |
2024 Inducement Stock Incentive Plan (as amended December 2024) Exhibit 10.2 ENANTA PHARMACEUTICALS, INC. 2024 Inducement Stock Incentive Plan (As amended through December 20, 2024) 1. Purpose The purpose of this 2024 Inducement Stock Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract persons who are expecte |
|
| February 11, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The un |
|
| February 10, 2025 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 • On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 • Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 • On Track to Announce STAT6 Deve |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| January 22, 2025 |
EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0. |
|
| December 9, 2024 |
Exhibit 99.1 Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) • Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 • Demonstrated a viral load declin |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 9, 2024 |
Phase 2 Study of Zelicapavir in Children: RSVPEDs Topline Results December 9, 2024 Exhibit 99. |
|
| November 27, 2024 |
Exhibit 10.31 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “Third Amendment”) is dated as of September 13, 2024, but made effective as of September 1, 2024, by and between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (“Landlord”), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parti |
|
| November 27, 2024 |
Exhibit 10.30 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) is made as of July 26, 2024, by and between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (“Landlord”), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS WHEREAS, Landlord and Tenant are now parties to that certain Deed of Lease dated as |
|
| November 27, 2024 |
Form of Notice of Grant of Restricted Stock Unit Award under 2024 Inducement Stock Incentive Plan Exhibit 10.27 Enanta Pharmaceuticals, Inc. RESTRICTED STOCK UNIT GRANT NOTICE AND AWARD AGREEMENT (2024 Inducement Stock INCENTIVE PLAN) This notice confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an award (this “Award”) of the number of Restricted Stock Units (the “RSUs”) set forth below pursuant to the Comp |
|
| November 27, 2024 |
Form of Notice of Grant of Non-Statutory Stock Option under 2024 Inducement Stock Incentive Plan Exhibit 10.26 Enanta Pharmaceuticals, Inc. NONSTATUTORY STOCK OPTION GRANT NOTICE AND AGREEMENT (2024 INDUCEMENT STOCK INCENTIVE PLAN) This Nonstatutory Stock Option Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) a Nonstatutory Stock Option (this “Option”) to purchase the number of shares of the |
|
| November 27, 2024 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 27, 2024 |
Amended and Restated Securities Trading Policy Exhibit 19.1 Amended and Restated Effective as of November 17, 2023 ENANTA PHARMACEUTICALS, INC. SECURITIES TRADING POLICY 1. BACKGROUND AND PURPOSE The federal securities laws prohibit any member of the Board of Directors (a “Director”) or employee of Enanta Pharmaceuticals, Inc. (the “Company”) (including its subsidiaries) from purchasing or selling Company securities on the basis of material no |
|
| November 27, 2024 |
Form of Performance Share Unit Certificate under 2024 Inducement Stock Incentive Plan Exhibit 10.28 ENANTA PHARMACEUTICALS, INC. 2024 Inducement Stock Incentive Plan Performance Share Unit Certificate This Performance Share Unit Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an award (this “Award”) of the number of Performance Share Units (“PSUs”) set forth above pursuant to the C |
|
| November 27, 2024 |
Exhibit 10.29 ENANTA PHARMACEUTICALS, INC. 2024 Inducement Stock Incentive Plan Relative Total Stockholder Return Unit Certificate This Relative Total Stockholder Return Unit Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an award (this “Award”) of the number of Relative Total Stockholder Return |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| November 27, 2024 |
Amended and Restated Compensation Clawback Policy Exhibit 97.1 Enanta pharmaceuticals, Inc. AMENDED AND RESTATED Compensation Clawback Policy (Effective as of October 2, 2023) 1. Purpose and Administration. Enanta Pharmaceuticals, Inc. (the “Company”) has adopted this amended and restated compensation clawback policy (the “Policy”) to provide for the recovery of certain executive compensation in the event of an accounting restatement resulting fr |
|
| November 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 25, 2024 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 • On Track to Report Topline Results for RSVPEDs, a Phase 2 Study of Zelicapavir in Infants and Children Infected with Respiratory Syncytial Virus (RSV), in December • Announced Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infec |
|
| November 14, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-enta093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| October 17, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 ENTASC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ENANTA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 29251M106 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the a |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 5, 2024 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 • Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 • Operations S |
|
| May 8, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 8, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 8, 2024 REGISTRATION NO. |
|
| May 8, 2024 |
EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Enanta Pharmaceuticals, Inc. |
|
| May 8, 2024 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ''Agreement") dated as of February 8, 2024, by and between Enanta Pharmaceuticals, Inc. (“Employer”), 500 Arsenal Street, Watertown, MA 02472, and Nathaniel S. Gardiner (“Employee”) amends and restates the Employment Agreement (the “Original Agreement”) dated as of April 28, 2014, between Em |
|
| May 8, 2024 |
2024 Inducement Stock Incentive Plan Exhibit 99.2 ENANTA PHARMACEUTICALS, INC. 2024 Inducement Stock Incentive Plan 1. Purpose The purpose of this 2024 Inducement Stock Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract persons who are expected to make important contributions to th |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 6, 2024 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024 • Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate |
|
| March 12, 2024 |
2019 Equity Incentive Plan (As amended March 2024) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 6, 2024) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected t |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 14, 2024 |
Enanta Pharmaceuticals, Inc. 500 Arsenal Street, Watertown, Massachusetts 02472 P: (617) 607-0800 February 14, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D. |
|
| February 14, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Enanta Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 07, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 7, 2024 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET • Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024 • Expanded into Immunology with New Discovery Program of Oral KIT Inhibitors for First I |
|
| February 6, 2024 |
[Remainder of this page intentionally left blank] February 5, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| January 26, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| January 11, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 ENTASC13G2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENANTA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 29251M106 (CUSIP Number) JANUARY 5, 2024 (Date of event which requires filing of this statement) Check the appropriate box to des |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Enanta Pharmaceuticals, Inc. |
|
| November 22, 2023 |
As filed with the Securities and Exchange Commission on November 22, 2023 As filed with the Securities and Exchange Commission on November 22, 2023 Registration Statement No. |
|
| November 22, 2023 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 22, 2023 |
Powers of Attorney (included on the signature pages to the registration statement) Table of Contents As filed with the Securities and Exchange Commission on November 22, 2023 Registration Statement No. |
|
| November 22, 2023 |
Exhibit 4.3 ENANTA PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.01 Issuable in Series 6 Section 2.02 Establishm |
|
| November 22, 2023 |
x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| November 20, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 20, 2023 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET • Initiated a Phase 2a Challenge Study of EDP-323,an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Report Data in Q3 2024 • Streamlined Business a |
|
| November 16, 2023 |
ENTA / Enanta Pharmaceuticals Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 ENTASC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENANTA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 29251M106 (CUSIP Number) NOVEMBER 7, 2023 (Date of event which requires filing of this statement) Check the appropriate box to design |
|
| August 8, 2023 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 8, 2023 S-8 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 8, 2023 REGISTRATION NO. |
|
| August 8, 2023 |
EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Enanta Pharmaceuticals, Inc. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 7, 2023 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 1 Study of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. • Cash and Ma |
|
| June 7, 2023 |
Company Logo Corporate Presentation June 7, 2023 Exhibit 99.1 Company Logo Corporate Presentation June 7, 2023 Company Logo Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statemen |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 8, 2023 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19 • Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Roy |
|
| May 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 27, 2023 |
EX-10.1 Exhibit 10.1 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN OMITTED. ROYALTY PURCHASE AGREEMENT BETWEEN ENANTA PHARMACEUTICALS, INC. AND OCM LIFE SCIENCES PORTFOLIO LP DATED AS OF APRIL 25, 2023 TABLE OF CO |
|
| April 27, 2023 |
EX-99.1 Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million • Non-Dilutive and Strengthens Balance Sheet • Competitive Process Results in the Sale of 54.5% of the MAVYRET®/MAVIRET® Royalty Interest, Subject to a 1.42x Cap • Sale Proceeds to |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 02, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 7, 2023 |
2019 Equity Incentive Plan (As amended March 2023) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 2, 2023) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected t |
|
| February 14, 2023 |
ENTA / Enanta Pharmaceuticals Inc / FIRST MANHATTAN CO Passive Investment SC 13G/A 1 firstmanhattan-enta123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 14, 2023 |
ENTA / Enanta Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-enta123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 9, 2023 |
ENTA / Enanta Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Enanta Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 7, 2023 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET • Completes Enrollment in SPRINT, a Phase 2 Clinical Study of EDP-235, a 3CL Protease Inhibitor Designed as an Oral, Once-Daily Treatment for COVID-19; Topline Data Expected in May • Expects Phase 1 Data of EDP-323, an L-Protein I |
|
| February 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 07, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 6, 2023 |
SC 13G/A 1 13ga4enanta.htm AMENDMENT #4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) * Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (Cusip Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) |
|
| January 20, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 23, 2022 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 21, 2022 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p. |
|
| November 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 26, 2022 |
EX-1.1 2 d376393dex11.htm EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 26, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Ag |
|
| August 26, 2022 |
Exhibit 107 Calculation Of Filing Fee Tables 424(b)(5) (Form Type) Enanta Pharmaceuticals, Inc. |
|
| August 26, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 26, 2022 |
Up to $100,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258632 PROSPECTUS SUPPLEMENT (To Prospectus dated August 9, 2021) Up to $100,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (sales agreement) with Jefferies LLC (Jefferies), dated August 26, 2022, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompa |
|
| August 8, 2022 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET ? Presented Positive Phase 1 Study Data for EDP-235, a Coronavirus 3CL Protease Inhibitor in Development as an Oral, Once-Daily Treatment for COVID-19; Phase 2 Study Planned to Start in 4Q 2022 ? Progressing Respiratory Syncytial Viru |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 17, 2022 |
Exhibit 10.1 Execution Version SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this ?Second Amendment?) is made as of May 12, 2022, by and between ARE-500 ARSENAL STREET, LLC, a Delaware limited liability company (?Landlord?), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of April |
|
| May 17, 2022 |
Lease Agreement made as of May 12, 2022 by and between ARE-MA Region No. 75, LLC and the Company Exhibit 10.3 Execution Version LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made as of this 12 day of May, 2022, between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (?Landlord?), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). Building: The to-be-constructed building in the Project to be located at The Arsenal on the Charles campus, Watertown, Mas |
|
| May 17, 2022 |
Exhibit 10.2 Execution Version FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this ?Amendment?) is made as of May 12, 2022, by and between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (?Landlord?), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). RECITALS WHEREAS, Landlord (as successor-in-interest to Athena Arsenal, LLC) and Tena |
|
| May 9, 2022 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET ? Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter ? Received Fast Track Designation for EDP-235, an Oral 3CL Protease Inhibitor Specifical |
|
| May 9, 2022 |
Form of Consulting Agreement (Amended and Restated), Nathalie Adda Exhibit 10.1 CONSULTING AGREEMENT (As Amended and Restated) This Consulting Agreement (this ?Agreement?) is entered into effective as of the 23rd day of February, 2022 (the ?Signature Date?) between Enanta Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, with offices at 500 Arsenal Street, Watertown, MA 02472, and Nathalie Adda, M.D, having a principal residence in Cambridge, Massach |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 9, 2022 |
EX-FILING FEES 4 d337268dexfilingfees.htm EX-FILING FEES EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Enanta Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 9, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 9, 2022 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 9, 2022 REGISTRATION NO. |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 03, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Commis |
|
| March 8, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 8, 2022 |
2019 Equity Incentive Plan (as amended through March 3, 2022) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 3, 2022) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this ?Plan?) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected t |
|
| February 15, 2022 |
Exhibit A AGREEMENT The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.01 per share, of Enanta Pharmaceuticals Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 15, 2022 |
ENTA / Enanta Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2022 |
ENTA / Enanta Pharmaceuticals Inc / FIRST MANHATTAN CO Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
ENTA / Enanta Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
Exhibit A AGREEMENT The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.01 per share, of Enanta Pharmaceuticals Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 10, 2022 |
ENTA / Enanta Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Enanta Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 8, 2022 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET ? Expects to Begin Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19, This Month ? Completed Enrollment in RSVP, a Phase 2b Study |
|
| February 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 08, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 4, 2022 |
ENTA / Enanta Pharmaceuticals Inc / Dworsky Alan J - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit |
|
| December 17, 2021 |
ENTA / Enanta Pharmaceuticals Inc / Luly Jay R. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (CUSIP Number) Nathaniel S. Gardiner Senior Vice President and General Counsel Enanta Pharmaceuticals, Inc. 500 Arsenal Street |
|
| November 24, 2021 |
Consulting Agreement with Nathalie Adda Exhibit 10.28 CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is entered into effective as of the 14th day of July, 2021 (the ?Signature Date?) between Enanta Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, with offices at 500 Arsenal Street, Watertown, MA 02472, and Nathalie Adda, M.D, having a principal residence in Cambridge, Massachusetts (?Consultant?) (each, |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 24, 2021 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 22, 2021 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET ? Presented First Preclinical Data for EDP-235, an Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19; First-in-Human Study Planned for Early 2022 ? Reported Positive Clini |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 9, 2021 |
As filed with the Securities and Exchange Commission on August 9, 2021 As filed with the Securities and Exchange Commission on August 9, 2021 Registration Statement No. |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 9, 2021 |
Exhibit 4.3 ENANTA PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [ ] Trustee - 1 - TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions. 1 Section 1.02 Other Definitions. 4 Section 1.03 Incorporation by Reference of Trust Indenture Act. 5 Section 1.04 Rules of Construction. 5 ARTICLE II THE SECURITIES 6 Section 2.01 Issuable in Series. 6 Section 2.02 |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 5, 2021 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET ? Nominates EDP-235, an Oral Protease Inhibitor Specifically Designed to Treat COVID-19, with a Phase 1 Study Planned for Early Q1 2022 ? On Track to Dose First Subject in a Phase 1 Study of EDP-721, an Oral, Hep |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 10, 2021 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2021 REGISTRATION NO. |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 6, 2021 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET ? Reported Positive Data from a Phase 1b Study of EDP-514 in NUC-Suppressed Chronic Hepatitis B Virus (HBV) Patients Supporting Once Daily Dosing and Combination Approach ? On Track to Report Preliminary Data f |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 5, 2021 |
2019 Equity Incentive Plan (As amended March 2021) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended March 2021) 1.Purpose The purpose of this 2019 Equity Incentive Plan (this ?Plan?) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make impor |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Enanta Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 8, 2021 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET • Broadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to Initiate Phase 1 Study Mid-2021 • Initiated RSVTx, |
|
| February 5, 2021 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| February 5, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Comm |
|
| February 5, 2021 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| January 28, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a- |
|
| January 21, 2021 |
- 2022 ENANTA PHARMACEUTICALS PROXY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| January 21, 2021 |
DEFA14A 1 enta-defa14a20210121.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only ( |
|
| December 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 25, 2020 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 25, 2020 |
Form of Notice of Restricted Stock Unit Award under 2019 Equity Incentive Plan. Form of Notice of Restricted Stock Unit Award under 2019 Equity Incentive Plan Exhibit 10. |
|
| November 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 23, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K Q4 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 23, 2020 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020 Webcast and Conference Call Today at 4:30 p.m. ET • On track to initiate a Phase 2b study in adult transplant patients with respiratory syncytial virus by year-end and a Phase 2 study in pediatric patients with respiratory syncytial virus in early 2021 |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 4, 2020 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET • Initiated Phase 1b Study of EDP-514 in Viremic HBV Patients and Resumed Phase 1b Study of EDP-514 in NUC-Suppressed HBV Patients; Preliminary Data Expected in 1H 2021 and 2Q 2021, Respectively • Plans to Initia |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 6, 2020 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET • On Track to Initiate Phase 1b Study of EDP-514 in Viremic Hepatitis B Patients in 2Q 2020 and Phase 1 Study of EDP-297 in 3Q 2020 • Royalty Revenue for the Quarter was $27.6 Million • Cash and Marketable Secu |
|
| March 4, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / Luly Jay R. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (CUSIP Number) Nathaniel S. Gardiner Senior Vice President and General Counsel Enanta Pharmaceuticals, Inc. 500 Arsena |
|
| March 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / SHIONOGI & CO LTD - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Enanta Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 10, 2020 |
Quarterly Report - ENTA_Q1_FY20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Comm |
|
| February 6, 2020 |
EX-99.1 Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019 Webcast and Conference Call Today at 4:30 p.m. ET • Positive results from part 1 of the Phase 1a/b clinical study of EDP-514 in healthy subjects • Part 2 initiated in nuc-suppressed chronic hepatitis B virus patients • Research and develo |
|
| January 23, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / Dworsky Alan J - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 17, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. DEFA14A - - DEFA14A DEFA14A 1 d820003ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as pe |
|
| January 17, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. DEF 14A - - DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 27, 2019 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 27, 2019 |
Description of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 EX-4.3 2 enta-ex43411.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of our common stock and a summary of our preferred stock. You should refer to our Restated Certificate of Incorporation (the “Certificate of Incorporation”) and our Amended and Restated Bylaws (the “Bylaws”), eac |
|
| November 21, 2019 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019 Webcast and Conference Call today at 4:30 p.m. ET • Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSV • EDP-297 selected as follow-on FXR agonist with differentiated preclinical profile • Royalty revenue for the quarter was |
|
| November 21, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2019 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 27, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. / FARALLON CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 9, 2019 |
Quarterly Report - Q3 2019 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 6, 2019 |
EX-99.1 2 enta-ex9916.htm EX-99.1 Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019 Webcast and Conference Call today at 4:30 p.m. ET • Royalty revenue for the quarter was $44.4 million • Phase 2a NASH data expected by the end of the third calendar quarter • Cash and marketable securities totaled $389.2 million at J |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2019 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. S-8 S-8 - 2019 AND 2012 EQUITY INCENTIVE PLANS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2019 REGISTRATION NO. |
|
| May 10, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. S-8 S-8 2012 EQUITY INCENTIVE PLAN AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2019 REGISTRATION NO. |
|
| May 10, 2019 |
EX-10.3 3 enta-ex10311.htm EX-10.3 Exhibit 10.3 Notice of Grant of Nonstatutory Stock Option {Non-Employee Directors} Enanta Pharmaceuticals, Inc. ID: 04-3205099 500 Arsenal Street Watertown, MA 02472 Optionholder: [Name and Address] Option Number: Plan: 2019 Equity Incentive Plan Effective (the Option Date), you (the Optionholder) have been granted a Nonstatutory Stock Option (this Option) to buy |
|
| May 10, 2019 |
Quarterly Report - Q2 2019 10-Q - MARCH 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 10, 2019 |
Form of Relative Total Stockholder Return Unit Certificate under 2019 Equity Incentive Plan. Exhibit 10.4 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan Relative Total Stockholder Return Unit Certificate rTSRU Certificate Number: rTSRU- rTSRUs This Relative Total Stockholder Return Unit Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an award (this “Award”) of the number of Relat |
|
| May 10, 2019 |
Form of Performance Share Unit Certificate under 2019 Equity Incentive Plan. Exhibit 10.5 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan Performance Share Unit Certificate PSU Certificate Number: PSU PSUs This Performance Share Unit Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an award (this “Award”) of the number of Performance Share Units (“PSUs”) set forth a |
|
| May 10, 2019 |
Form of Notice of Grant of Non-Statutory Stock Option under 2019 Equity Incentive Plan. EX-10.2 2 enta-ex10212.htm EX-10.2 Exhibit 10.2 Notice of Grant of Nonstatutory Stock Option Enanta Pharmaceuticals, Inc. ID: 04-3205099 500 Arsenal Street Watertown, MA 02472 [Name] [Address] Option Number: Plan: 2019 Equity Incentive Plan Effective , you (the Optionholder) have been granted a Nonstatutory Stock Option (this Option) to buy shares of Enanta Pharmaceuticals, Inc. (the Company) Comm |
|
| May 7, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2019 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Commissio |
|
| May 7, 2019 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2019 Webcast and Conference Call today at 4:30 p.m. ET • Data from Phase 2a RSV program anticipated mid-2019 and Phase 2a NASH program by the end of third quarter of calendar 2019 • Royalty revenue for the quarter was $39.6 million • Cash and marketable securities total |
|
| March 7, 2019 |
Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan 1.Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to th |
|
| March 7, 2019 |
8-K/A 1 enta-8ka20190228.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2019 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or othe |
|
| March 6, 2019 |
Submission of Matters to a Vote of Security Holders 8-K 1 enta-8k20190228.htm 8-K PROXY VOTE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2019 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or |
|
| February 14, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. / VANGUARD GROUP INC Passive Investment enantapharmaceuticalsinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Enanta Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the |
|
| February 11, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. / FIRST MANHATTAN CO - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ENANTA PHARMACEUTICALS INC (Name of Issuer) COMMON (Title of Class of Securities) 29251M106 (CUSIP Number) Calendar Year 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| February 8, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 8, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. / Dworsky Alan J - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 6, 2019 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018 Webcast and Conference Call today at 4:30 p.m. ET • Royalty revenue for the quarter increased to $69.9 million • Research and development programs progressing well with clinical milestones expected in 2019 in our RSV, NASH, and HBV programs • Cas |
|
| February 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2019 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Comm |
|
| January 18, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| January 18, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a- |
|
| January 18, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. / Luly Jay R. - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (CUSIP Number) Nathaniel S. Gardiner Senior Vice President and General Counsel Enanta Pharmaceuticals, Inc. 500 Arsenal S |
|
| November 29, 2018 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 29, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 29, 2018 |
Lease Agreement between Company and Athena Arsenal, LLC, dated as of September 27, 2018. EX-10.10 2 enta-ex1010399.htm EX-10.10 Exhibit 10.10 Execution copy ENANTA PHARMACEUTICALS, INC. The Arsenal on the Charles, Watertown Exhibit 1, Lease Data Execution Date: September 24, 2018 Landlord: Athena Arsenal, LLC, a Massachusetts Limited Liability Company. Landlord’s Notice Address: 311 Arsenal Street, The Arsenal on the Charles, Watertown, MA 02472, Attn: Mark Blair. Landlord’s Rent Addr |
|
| November 26, 2018 |
EX-99.1 Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018 Webcast and Conference Call today at 4:30 p.m. ET • Royalty revenue for the quarter increased to $67.2 million • Net income was $27.4 million, or $1.30 per diluted common share • Cash and marketable securities totaled $325.1 million • Phase 2a |
|
| November 26, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 d657691d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 26, 2018 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdicti |
|
| August 9, 2018 |
ENTA / Enanta Pharmaceuticals, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 7, 2018 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018 Webcast and Conference Call today at 4:30 p.m. ET • Royalty revenue for the quarter increased to $57.3 million, a quarter-to-quarter increase of 30% • Net income was $20.3 million, or $0.97 per diluted common share • Preliminary Phase 1 results demonstrate that RSV c |
|
| August 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 7, 2018 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2018 |
ENTA / Enanta Pharmaceuticals, Inc. Q2 2018 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 10, 2018 |
ENTA / Enanta Pharmaceuticals, Inc. / FARALLON CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2018 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Commissio |
|
| May 8, 2018 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2018 Webcast and Conference Call today at 4:30 p.m. ET • Royalty revenue for the quarter increased to $44.0 million due to increase in AbbVie’s MAVYRET™ sales • Net income for the quarter was $12.6 million, or $0.61 per diluted common share • Fast Track designation gran |
|
| March 2, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 enta-8k20180228.htm 8-K PROXY VOTE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2018 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or |
|
| February 9, 2018 |
ENTA / Enanta Pharmaceuticals, Inc. / FIRST MANHATTAN CO - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* ENANTA PHARMACEUTICALS INC (Name of Issuer) COMMON (Title of Class of Securities) 29251M106 (CUSIP Number) Calendar Year 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2018 |
ENTA / Enanta Pharmaceuticals, Inc. / FIRST MANHATTAN CO - NONE Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. n/a )* ENANTA PHARMACEUTICALS INC (Name of Issuer) COMMON (Title of Class of Securities) 29251M106 (CUSIP Number) Calendar Year 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 9, 2018 |
ENTA / Enanta Pharmaceuticals, Inc. Q1'18 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 7, 2018 |
enta-ex9916.htm Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017 Webcast and Conference Call today at 4:30 p.m. ET ? Total revenue for the quarter was $38.1 million ? Net income for the quarter was $11.7 million, or $0.59 per diluted common share ? Cash and marketable securities totaled $297.5 million at Decemb |
|
| February 7, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 enta-8k20180207.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2018 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisd |
|
| January 22, 2018 |
ENTA / Enanta Pharmaceuticals, Inc. / Dworsky Alan J - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 19, 2018 |
ENTA / Enanta Pharmaceuticals, Inc. DEFA14A DEFA14A 1 d474587ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as pe |
|
| January 19, 2018 |
ENTA / Enanta Pharmaceuticals, Inc. DEF 14A DEF 14A 1 enta-def14a20180228.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (a |
|
| December 11, 2017 |
enta-s8.htm AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON DECEMBER 11, 2017 REGISTRATION NO. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 04-3205099 (State or other jurisdiction of incorporation or or |
|
| December 11, 2017 |
Form of Performance Share Unit Certificate under 2012 Equity Incentive Plan. EX-10.18 3 enta-ex10181136.htm EX-10.18 Exhibit 10.18 ENANTA PHARMACEUTICALS, INC. 2012 Equity Incentive Plan Performance Share Unit Certificate PSU Certificate Number: PSU PSUs This Performance Share Unit Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an award (this “Award”) of the number of Per |
|
| December 11, 2017 |
Enanta Pharmaceuticals, Inc. Subsidiaries of the Company EX-21.1 5 enta-ex21112.htm EX-21.1 Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| December 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| December 11, 2017 |
Form of Relative Total Stockholder Return Unit Certificate under 2012 Equity Incentive Plan. EX-10.19 4 enta-ex10191137.htm EX-10.19 Exhibit 10.19 ENANTA PHARMACEUTICALS, INC. 2012 Equity Incentive Plan Relative Total Stockholder Return Unit Certificate rTSRU Certificate Number: rTSRU- rTSRUs This Relative Total Stockholder Return Unit Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an aw |
|
| December 11, 2017 |
Specimen certificate evidencing shares of Series 1 Non-Convertible Preferred Stock EX-4.3 2 enta-ex431302.htm EX-4.3 Exhibit 4.3 The shares of stock represented by this certificate have not been registered or qualified under the Securities Act of 1933, as amended (the “Act”), or applicable state securities laws and may not be sold, transferred, assigned or otherwise disposed of unless registered or qualified under the Act and such laws or an opinion of counsel satisfactory to th |
